Tissue injury can lead to a fibrotic disease, for example lethal cirrhosis in the liver. In the cirrhotic stage, the disease is difficult to cure because of the excessive production of scar tissue caused by elevated crosslinking of extracellular matrix (ECM). So far, the clinical trials targeting the most widely reported ECM crosslinking mechanism of liver cirrhosis namely lysyl oxidase (LOX) unfortunately show no efficacy. This raises the question whether there is another, more significant contributor to the crosslinking of ECM in the disease.